PONATINIB HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE).
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
| Metabolism | Metabolized primarily by CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, CYP3A5, and esterases. |
| Excretion | Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug. |
| Half-life | Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days. |
| Protein binding | 92–99% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd/F approximately 1100–1200 L (not weight-adjusted; if estimated at 70 kg, ~15.7–17.1 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Absolute oral bioavailability is not determined; relative bioavailability after oral administration is adequate; absorption is unaffected by food, though high-fat meal reduces Cmax by ~21% and delays Tmax by 2 hours. |
| Onset of Action | Oral: Clinical response (reduction in WBC counts in CML) observed within 1–2 weeks, with maximal cytogenetic response typically after 3–6 months. |
| Duration of Action | Once-daily dosing maintains continuous target inhibition; duration of molecular response is sustained with continued therapy; median duration of response in clinical trials varies but is typically months to years depending on disease phase. |
| Molecular Weight | 532.56 |
45 mg orally once daily with or without food.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min), reduce dose to 30 mg once daily. |
| Liver impairment | For Child-Pugh A or B, reduce starting dose to 30 mg once daily. For Child-Pugh C, reduce starting dose to 30 mg once daily and monitor closely; further dose reductions may be considered based on tolerability. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no approved dosing guidelines. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and consider age-related decline in CrCl for dose adjustments per renal impairment guidelines. |
| 1st trimester | Contraindicated due to teratogenicity; animal studies show embryo-fetal toxicity and malformations. |
| 2nd trimester | Contraindicated; risk of fetal harm outweighs potential benefits. |
| 3rd trimester | Contraindicated; may cause fetal harm or neonatal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE).
| Placental transfer | Ponatinib is expected to cross the placenta based on molecular weight and animal studies showing fetal distribution. |
| Breastfeeding | Ponatinib is excreted in rat milk; no human data. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose. |
■ FDA Black Box Warning
WARNING: ARTERIAL THROMBOTIC EVENTS, HEPATOTOXICITY, AND HEART FAILURE. Ponatinib has been associated with life-threatening arterial thrombosis, including myocardial infarction and stroke. Also associated with severe hepatotoxicity and heart failure. Use only in patients with resistance or intolerance to prior TKI therapy.
| Serious Effects |
Hypersensitivity to ponatinib or any component of the formulationPregnancy
| Precautions | Arterial thrombotic events (including MI, stroke), Venous thromboembolic events, Heart failure, Hepatotoxicity, Pancreatitis, Hemorrhage, Hypertension, Fluid retention, Wound healing complications, Tumor lysis syndrome |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase ponatinib concentrations. No other significant food interactions are known. Take with or without food. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) |
| Teratogenic Risk | Ponatinib is embryotoxic and fetotoxic in animal studies at exposures below human therapeutic levels. First trimester: No adequate human data; avoid use unless benefit > risk. Second/third trimester: Potential for fetal harm based on animal findings; use only if clearly needed. |
| Fetal Monitoring | Monitor complete blood counts, liver function, serum lipase, and blood pressure. Assess for signs of pancreatitis, hepatotoxicity, hemorrhage, and arterial thrombotic events. Fetal ultrasound to monitor growth if used during pregnancy. |
| Fertility Effects | Ponatinib may impair male and female fertility based on animal studies (reduced sperm count, testicular tubular atrophy, ovarian effects). Human data lacking. |
| Clinical Pearls | Monitor for arterial thrombotic events, hepatotoxicity, and pancreatitis. Assess blood pressure, LFTs, and lipase at baseline and regularly. Ponatinib is associated with high risk of vascular occlusion; avoid in patients with history of MI or stroke unless benefit outweighs risk. Use with caution in patients with cardiovascular risk factors. Discontinue if evidence of vascular occlusion or thrombosis. Dose reduction may be considered for adverse reactions. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily with or without food. · Swallow tablets whole; do not crush, chew, or break them. · If you miss a dose, take it as soon as you remember unless it is within 12 hours of the next dose; do not double up. · You will need regular blood tests to monitor for side effects like liver problems, pancreatitis, and blood pressure changes. · Seek immediate medical attention if you experience chest pain, shortness of breath, sudden weakness, or severe abdominal pain. · Avoid grapefruit and grapefruit juice during treatment, as they may increase drug levels and risk of side effects. · Use effective contraception during treatment and for at least 3 weeks after stopping, as ponatinib can harm an unborn baby. · Do not breastfeed while taking ponatinib and for 3 weeks after the last dose. |